ArrowMark Colorado Holdings LLC Purchases 532,105 Shares of Arvinas, Inc. (NASDAQ:ARVN)

ArrowMark Colorado Holdings LLC grew its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 42.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,776,555 shares of the company's stock after purchasing an additional 532,105 shares during the period. ArrowMark Colorado Holdings LLC owned about 2.59% of Arvinas worth $34,057,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. KBC Group NV lifted its stake in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after acquiring an additional 1,255 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas in the fourth quarter worth about $171,000. Teacher Retirement System of Texas boosted its stake in shares of Arvinas by 19.0% during the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock worth $274,000 after acquiring an additional 2,280 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Arvinas by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after acquiring an additional 1,367 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Arvinas during the fourth quarter worth approximately $332,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Price Performance

Shares of ARVN traded down $0.68 during mid-day trading on Tuesday, reaching $6.95. The company had a trading volume of 2,918,678 shares, compared to its average volume of 1,270,020. The company has a market capitalization of $507.29 million, a P/E ratio of -2.51 and a beta of 2.21. Arvinas, Inc. has a twelve month low of $5.94 and a twelve month high of $37.38. The company's 50-day moving average is $9.26 and its 200-day moving average is $17.16.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the previous year, the firm earned ($0.97) earnings per share. The business's revenue for the quarter was up 646.2% compared to the same quarter last year. As a group, equities analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

In other news, insider Noah Berkowitz sold 8,658 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock worth $769,402 over the last ninety days. Corporate insiders own 5.23% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARVN. Morgan Stanley decreased their price objective on shares of Arvinas from $48.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday, March 13th. Wells Fargo & Company dropped their price objective on Arvinas from $26.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday. Piper Sandler restated an "overweight" rating and set a $14.00 target price (down previously from $24.00) on shares of Arvinas in a research note on Friday. Guggenheim dropped their price target on Arvinas from $32.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday. Finally, TD Cowen cut Arvinas from a "buy" rating to a "hold" rating in a research report on Friday. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.97.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.